SecBot SecBot

NVCT

Nuvectis Pharma, Inc.
Nasdaq· Pharmaceutical Preparations· Inc. DE· CIK 0001875558 Biotech & Drug Discovery
$18.49 −1.56 (−7.78%)
Oct 26 4:00 PM ET · prev $20.05
Market cap
$681.3M
Small cap
Consensus
Buy
92% Buy or better · 12 analysts
Median target
$35.00
+89% · range $30.00–40.00
Next earnings
Nov 10
in 15 days
1 year
+182.3%
from $6.55 · Oct 27
30 days
−11.1%
from $20.81
52-week range
$5.65–28.53
−35% from high · low Nov 5
Avg volume 20D
178.0K
shares / day
Short interest
🔒 Subscribers only
Insider net
+$1.2M
2 buyers · 0 sellers · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
7
analyzed by SecBot
SecBot read BULLISH 1 report · 90 days
Balance 0 bearish · 1 bullish oldest → newest, height = score
Avg score ·High conf. 1/1 ·Next Earnings date, Nov 10, 2026
Strongest BULLISH Nuvectis Pharma reported Q2 2026 results highlighting a transformative in-licensing of ciprocopan (NXP100)…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersBULLISH

    2 insiders bought $1.2M at an average $18.66. No open-market sales.

  • InstitutionsBULLISH

    Q2 2026: 18 added (0 new), 2 trimmed or exited.

  • AnalystsBULLISH

    11 of 12 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    15% below its 50-day average.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.ADD1,001,285$18.4M
VANGUARD CAPITAL MANAGEMENT LLCADD872,482$16.0M
STATE STREET CORPADD248,198$4.6M
SUSQUEHANNA INTERNATIONAL GROUP, LLPDOUBLED217,286$4.0M
VANGUARD PORTFOLIO MANAGEMENT LLCADD118,297$2.2M
CITADEL ADVISORS LLCADD115,532$2.1M
UBS Group AGADD69,200$1.3M
CIBC Bancorp USA Inc.DOUBLED67,155$917.7K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

12 analysts
Buy 92% rate it Buy or better
Strong Buy2Buy9Hold1Sell0Strong Sell0
12-month targets · 5 analysts

Price is below the lowest target. Median implies +89%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 24, 2026HC Wainwright & Co.
REITERATE
REITERATEBuy
Aug 24, 2026Cantor Fitzgerald
INITIATE
INITIATEOverweight
Jul 6, 2026Roth Capital
MAINTAIN
MAINTAINBuy
Jun 22, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy
Jun 12, 2026HC Wainwright & Co.
MAINTAIN
MAINTAINBuy

Insider ledger

Form 4
$1.2M
bought · 2 insiders
$0
sold · 0 insiders
−0.9%
vs their $18.66 cost
DateInsiderTypeValue
Aug 3, 2026
Carson Michael J.
Vice President, Finance
AWARD30,000 sh
Jun 30, 2026
BENTSUR RON
Chairman & CEO
BUY$250.0K
Jun 30, 2026
Mosseri Marlio Charles
10%+ Owner
BUY$916.0K
Jun 11, 2026
Sanchez Juan
Director
AWARD35,000 sh
Jun 11, 2026
Oliviero James F III
Director
AWARD35,000 sh
Jun 11, 2026
Kaplan Matthew L.
Director
AWARD35,000 sh
Jun 11, 2026
Hoberman Kenneth
Director
AWARD35,000 sh

Earnings setup

Estimates
Nov 10
reports in 15 days

Revision history: 🔒 Fresh data, subscribers only

PeriodEPS est.Range30D rev.Revenue
Current Q🔒 Fresh data, subscribers only
Next Q🔒 Fresh data, subscribers only
Current FY🔒 Fresh data, subscribers only
Next FY🔒 Fresh data, subscribers only
Reddit

Fresh Reddit data

The last 24 hours of Reddit activity are for subscribers.

Subscribe for Full Access
Recent posts
r/investing_discussion1d ago
Fresh post, for subscribers
Recent comments
r/investing_discussion1d ago
Fresh comment, for subscribers
All social signals and their track records

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Sep 30, 2026 Short interest report
Short Interest: NVCT up 7% to 2.5M shares
Settlement 2026-09-30 | Days to cover: 10.34 | ≈7.73% of shares outstanding (est.)
Aug 4, 2026 SEC
Nuvectis Pharma reported Q2 2026 results highlighting a transformative in-licensing of ciprocopan (NXP100) and NXP200…
8-K — Impact 7/10
Aug 3, 2026 Insider
Carson Michael J. was granted 30,000 shares
Vice President, Finance
Jun 30, 2026 SEC
Nuvectis Pharma priced a $100 million public offering of 5 million shares at $20 per share, a 30% discount to the…
8-K — Impact 6/10
Jun 29, 2026 Press
Nuvectis Pharma priced an underwritten public offering of 5,000,000 shares at $20.00/share for gross proceeds of $100…
Impact 6/10
Jun 30, 2026 Insider
BENTSUR RON bought 12,500 shares
Chairman & CEO @ $20.00 ($250.0K)
Jun 30, 2026 Insider
Mosseri Marlio Charles bought 50,000 shares
10%+ Owner @ $18.32 ($916.0K)
Jun 30, 2026 Inst.
BlackRock, Inc. — ADD
1,001,285 shares ($18.4M)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 10, 2026
Earnings date
NVCT Q3 2026 Earnings Scheduled — 2026-11-10
Recent
Sep 30, 2026
Short interest
Short Interest: NVCT up 7% to 2.5M shares
Settlement 2026-09-30 | Days to cover: 10.34 | ≈7.73% of shares outstanding (est.)
Aug 11, 2026
Earnings date
NVCT Q2 2026 Earnings Scheduled — 2026-08-11
Aug 4, 2026
Earnings
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
FORT LEE, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage…
Aug 3, 2026
Earnings date
NVCT Q2 2026 Earnings Scheduled — 2026-08-03
Jul 31, 2026
Short interest
Short Interest: NVCT up 22% to 1.8M shares
Settlement 2026-07-31 | Days to cover: 7.40 | ≈5.66% of shares outstanding (est.)

SecBot reports

7 filings · 1 press release · 2 bullish · 3 bearish · 2 neutral
All NVCT filing & press-release reports (8)